Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Acute Lymphoblastic Leukemia (ALL) Outcomes after Allogeneic Blood or Marrow Transplantation (alloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) in the Era of More Effective Pre-Transplant Therapy

Blood (2024) 144 (Supplement 1): 3551.

https://doi.org/10.1182/blood-2024-212141

Published: 2024

Journal Articles

Favorable Outcomes for High-Risk MDS and Oligoblastic AML with MDS-Related Changes with Reduced Intensity Allogeneic Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide

Ilias Sinanidis, Michael Jamie Hochman, Hua-Ling Tsai, Michael P Randall, Brandon Bonilla, Ravi Varadhan, Alexander Joseph Ambinder, Amy E. DeZern, Theodoros Karantanos

Blood (2023) 142 (Supplement 1): 3229.

https://doi.org/10.1182/blood-2023-187247

Published: 2023

Journal Articles

A Phase I Trial of Activated Donor-Derived Marrow Infiltrating Lymphocytes to Treat Relapsed Hematologic Malignancies after Allogeneic Transplantation with Post-Transplantation Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis

Joseph Rimando, Francesco Mazziotta, Alison Gareau, Maria Bettinotti, Jonathan Allen Webster, Syed Abbas Ali, Philip Imus, Mario Victor Lemas, Amy E. DeZern, Mark J. Levis, Marianna Zahurak, Ravi Varadhan, Richard F. Ambinder, Carol Huff, Ivana Gojo, Richard J. Jones, Ivan M. Borrello, Leo Luznik

Blood (2023) 142 (Supplement 1): 3473.

https://doi.org/10.1182/blood-2023-179394

Published: 2023

Journal Articles

Allogeneic Blood or Marrow Transplantation (alloBMT) Using Haploidentical Grandchildren Donors and Post-Transplant Cyclophosphamide (PTCy) -Based Gvhd Prophylaxis

Yosra M. Aljawai, Hua-Ling Tsai, Ravi Varadhan, Richard J. Jones, Philip H. Imus

Blood (2022) 140 (Supplement 1): 4721–4722.

https://doi.org/10.1182/blood-2022-169028

Published: 2022

Journal Articles

Cell-Free DNA (cfDNA)-Based Measurable Residual Disease (MRD) Detection As a Predictor of Relapse Post-Allogeneic Blood or Marrow Transplant (alloBMT) in Patients with Myeloid Malignancies

Sergiu Pasca, Matthew Guo, Shiyu Wang, Kristin Stokvis, Audra Shedeck, Aparna Pallavajjala, Lisa Haley, Cynthia Shams, Roshni Pallavajjala, Christopher D. Gocke, Amy E. DeZern, Ravi Varadhan, Richard J. Jones, Lukasz P. Gondek

Blood (2022) 140 (Supplement 1): 3429–3430.

https://doi.org/10.1182/blood-2022-169413

Published: 2022

Journal Articles

Haploidentical Donor Transplantation with Posttransplantation Cyclophosphamide in Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Institutional Collaboration of 14 Centers

Blood (2022) 140 (Supplement 1): 7731–7733.

https://doi.org/10.1182/blood-2022-157985

Published: 2022

Journal Articles

Allogeneic Blood or Marrow Transplantation (AlloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) for Acute Lymphoblastic Leukemia (ALL) in Patients Aged ≥ 55: Best Results in B ALL in First Remission (CR1) with Reduced-Intensity Conditioning (RIC)

Blood (2022) 140 (Supplement 1): 4813–4815.

https://doi.org/10.1182/blood-2022-171038

Published: 2022

Journal Articles

Diminished ovarian reserve in young women with sickle cell anemia

Lydia H. Pecker, Sarah Hussain, Jaanvi Mahesh, Ravi Varadhan, Mindy S. Christianson, Sophie Lanzkron

Blood (2022) 139 (7): 1111–1115.

https://doi.org/10.1182/blood.2021012756

Published: 2022

Includes: Supplemental data

Journal Articles

Signatures of GVHD and relapse after posttransplant cyclophosphamide revealed by immune profiling and machine learning

Shannon R. McCurdy, Vedran Radojcic, Hua-Ling Tsai, Ante Vulic, Elizabeth Thompson, Sanja Ivcevic, Christopher G. Kanakry, Jonathan D. Powell, Brian Lohman, Djamilatou Adom, Sophie Paczesny, Kenneth R. Cooke, Richard J. Jones, Ravi Varadhan, Heather J. Symons, Leo Luznik

Blood (2022) 139 (4): 608–623.

https://doi.org/10.1182/blood.2021013054

Published: 2022

Includes: Supplemental data

Journal Articles

The Presence of SETBP1 , RUNX1 or EZH2 Mutation in MDS/MPN Is Associated with Absence of Response to Hypo-Methylating Agents

Theodoros Karantanos, Hua-Ling Tsai, Mark Levis, Ravi Varadhan, Richard J. Jones, Tania Jain

Blood (2021) 138 (Supplement 1): 1520.

https://doi.org/10.1182/blood-2021-151624

Published: 2021

Journal Articles

Allogeneic Blood or Marrow Transplantation (BMT) with Post-Transplantation Cyclophosphamide (PTCy) Based Graft Versus Host Disease (GVHD) Prophylaxis for Myelodysplastic Syndrome/ Myeloproliferative Neoplasm-Overlap Syndromes (MDS/MPN)

Theodoros Karantanos, MDPhD, Hua-Ling Tsai, ScM, Lukasz P. Gondek, MDPhD, Mark Levis, MD PhD, Margaret M. Showel, MD, Amy E. DeZern, MD, Ivana Gojo, MD, Ravi Varadhan, PhD, Richard J. Jones, MD, Tania Jain, MD

Blood (2020) 136 (Supplement 1): 40.

https://doi.org/10.1182/blood-2020-138671

Published: 2020

Journal Articles

Transplant Outcomes for IDH-Mutated AML: Good Outcomes Thanks to Keeping Good Company

Alexander Joseph Ambinder, MDMPH, Matthew L Smith, Ravi Varadhan, PhD, Amy E. DeZern, MD, Mark Levis, MD PhD, Gabriel Ghiaur, MD PhD, Richard J. Jones, MD, B. Douglas Smith, MD

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-141493

Published: 2020

Journal Articles

Hydroxyurea Is a Potential Risk Factor for Diminished Ovarian Reserve in Young Adults with Sickle Cell Anemia

Lydia H. Pecker, MD, Sarah Hussain, Jaanvi Mahesh, Ravi Varadhan, PhD, Mindy S Christianson, MD MBA, Sophie M. Lanzkron, MD MHS

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-136011

Published: 2020

Journal Articles

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Ivana Gojo, MD, Robert K. Stuart, MD, Jonathan Webster, MD, Amanda Blackford, MS, Juan Carlos Varela, MD PhD, Jillian Morrow, RN, Amy E. DeZern, MD, Matthew C Foster, MD, Mark J. Levis, MD, Catherine C. Coombs, MD, Gabrielle T. Prince, MD, B. Douglas Smith, MD, Hendrik W. Van Deventer, MD, Katarzyna Jamieson, MD, Ravi Varadhan, PhD, Benjamin G. Vincent, MD, Jonathan S Serody, MD, Leo Luznik, MD, Joshua F Zeidner, MD

Blood (2019) 134 (Supplement_1): 832.

https://doi.org/10.1182/blood-2019-127345

Published: 2019

Journal Articles

Patient Satisfaction of Care in the Treatment of Vaso-Occlusive Crises: A Comparison of Emergency Department and Infusion Centers in the Escaped Study

Blood (2018) 132 (Supplement 1): 314.

https://doi.org/10.1182/blood-2018-99-111544

Published: 2018

Journal Articles

A Five Fold Decrease in Admissions for Uncomplicated Vaso-Occlusive Crisis and Other Benefits from Care in Infusion Clinics: Results from the Escaped Trial

Blood (2018) 132 (Supplement 1): 853.

https://doi.org/10.1182/blood-2018-99-111484

Published: 2018

Journal Articles

Nonmyeloablative (NMA), HLA-Haploidentical (Haplo) Blood or Marrow Transplantation (BMT) from Non-First-Degree Related Donors Has Similar Outcomes to First-Degree Related BMT

Hany Elmariah, MDMS, Yvette L Kasamon, MD, Marianna Zahurak, MS, Noah Tucker, CCRC, Gary Rosner, ScD, F Javier Bolanos-Meade, MD, Ravi Varadhan, PhD, Ephraim J. Fuchs, MD MBA, Amy E. DeZern, MD, Leo Luznik, MD, Richard J. Jones, PhD, Richard F Ambinder, MD

Blood (2017) 130 (Supplement 1): 3304.

https://doi.org/10.1182/blood.V130.Suppl_1.3304.3304

Published: 2017

Journal Articles

Men with Sickle Cell Disease Show Significant Concerns over Safety While Being Treated for Vaso-Occlusive Crises: Preliminary Observations from the Escaped Trial

Blood (2017) 130 (Supplement 1): 129.

https://doi.org/10.1182/blood.V130.Suppl_1.129.129

Published: 2017

Journal Articles

The Fountain of Youth: Outcomes of Nonmyeloablative (NMA), HLA-Haploidentical Related (Haplo) Bone Marrow Transplantation (BMT) with Post-Transplantation Cyclophosphamide (PTCy) Best with Younger Donors Regardless of Relationship to Patient

Clio E Franklin, MBBS, BSc, MRCP, Margaret M. Showel, MD, Hua-Ling Tsai, ScM, Ravi Varadhan, PhD, Shannon R. McCurdy, MD, Douglas E. Gladstone, MD, Richard J. Jones, MD, Amy E. DeZern, MD

Blood (2017) 130 (Supplement 1): 849.

https://doi.org/10.1182/blood.V130.Suppl_1.849.849

Published: 2017

Journal Articles

Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide

Blood (2017) 129 (10): 1389–1393.

https://doi.org/10.1182/blood-2016-09-737825

Published: 2017

Includes: Supplemental data

NARROW

Acute Lymphoblastic Leukemia (ALL) Outcomes after Allogeneic Blood or Marrow Transplantation (alloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) in the Era of More Effective Pre-Transplant Therapy

Favorable Outcomes for High-Risk MDS and Oligoblastic AML with MDS-Related Changes with Reduced Intensity Allogeneic Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide

A Phase I Trial of Activated Donor-Derived Marrow Infiltrating Lymphocytes to Treat Relapsed Hematologic Malignancies after Allogeneic Transplantation with Post-Transplantation Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis

Allogeneic Blood or Marrow Transplantation (alloBMT) Using Haploidentical Grandchildren Donors and Post-Transplant Cyclophosphamide (PTCy) -Based Gvhd Prophylaxis

Cell-Free DNA (cfDNA)-Based Measurable Residual Disease (MRD) Detection As a Predictor of Relapse Post-Allogeneic Blood or Marrow Transplant (alloBMT) in Patients with Myeloid Malignancies

Haploidentical Donor Transplantation with Posttransplantation Cyclophosphamide in Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Institutional Collaboration of 14 Centers

Allogeneic Blood or Marrow Transplantation (AlloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) for Acute Lymphoblastic Leukemia (ALL) in Patients Aged ≥ 55: Best Results in B ALL in First Remission (CR1) with Reduced-Intensity Conditioning (RIC)

Diminished ovarian reserve in young women with sickle cell anemia

Signatures of GVHD and relapse after posttransplant cyclophosphamide revealed by immune profiling and machine learning

The Presence of SETBP1 , RUNX1 or EZH2 Mutation in MDS/MPN Is Associated with Absence of Response to Hypo-Methylating Agents

Allogeneic Blood or Marrow Transplantation (BMT) with Post-Transplantation Cyclophosphamide (PTCy) Based Graft Versus Host Disease (GVHD) Prophylaxis for Myelodysplastic Syndrome/ Myeloproliferative Neoplasm-Overlap Syndromes (MDS/MPN)

Transplant Outcomes for IDH-Mutated AML: Good Outcomes Thanks to Keeping Good Company

Hydroxyurea Is a Potential Risk Factor for Diminished Ovarian Reserve in Young Adults with Sickle Cell Anemia

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Patient Satisfaction of Care in the Treatment of Vaso-Occlusive Crises: A Comparison of Emergency Department and Infusion Centers in the Escaped Study

A Five Fold Decrease in Admissions for Uncomplicated Vaso-Occlusive Crisis and Other Benefits from Care in Infusion Clinics: Results from the Escaped Trial

Nonmyeloablative (NMA), HLA-Haploidentical (Haplo) Blood or Marrow Transplantation (BMT) from Non-First-Degree Related Donors Has Similar Outcomes to First-Degree Related BMT

Men with Sickle Cell Disease Show Significant Concerns over Safety While Being Treated for Vaso-Occlusive Crises: Preliminary Observations from the Escaped Trial

The Fountain of Youth: Outcomes of Nonmyeloablative (NMA), HLA-Haploidentical Related (Haplo) Bone Marrow Transplantation (BMT) with Post-Transplantation Cyclophosphamide (PTCy) Best with Younger Donors Regardless of Relationship to Patient

Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only